Zaikina T. S., Rynchak P. I., Tytova G. Yu., Zaliubovska O. I., Lantukhova N. D.

NEW ERA IN THE TREATMENT OF CHRONIC HEART FAILURE

---

Show/Download

About the author:

Zaikina T. S., Rynchak P. I., Tytova G. Yu., Zaliubovska O. I., Lantukhova N. D.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

Heart failure remains one of the leading medical problems in the world. In recent years, there have been significant changes in approaches to the treatment of patients with chronic heart failure. The aim of the study - summarization of existing scientific data on the effects of recently discovered drugs and analysis of current clinical trials aimed at evaluating of experimental drugs in patients with chronic heart failure. Positive effects of sodium-glucose cotransporter-2 inhibitors found in the several studies allowed to include them in the European guidelines for the treatment of patients with chronic heart failure regardless of the ejection fraction of the left ventricle. Vericiguat is recommended for patients with chronic heart failure NYHA class II-IV and reduced left ventricular ejection fraction, who experienced decompensation of heart failure in the recent 3 months, despite receiving optimal therapy of chronic heart failure. Omecamtiv mecarbil, an activator of cardiac myosin, was considered one of the promising drugs for the treatment of heart failure due to its ability to reduce primary composite endpoint compared to placebo. However, in 2023 the US Food and Drug Administration refused to approve omecamtiv mecarbil for the treatment of adult patients with heart failure with reduced left ventricular ejection fraction, citing a lack of sufficient evidence of the drug's effectiveness. Development of new medicines for patients with chronic heart failure provides new opportunities for improving the quality of life and prognosis of patients. Sodium-glucose cotransporter-2 inhibitors, vericiguat, which are already on the pharmaceutical market, show impressive results in reducing symptoms, preventing decompensation and prolonging the life of patients. Ongoing clinical studies of experimental drugs give hope for breakthrough results.

Tags:

Bibliography:

1. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Burden of Heart Failure: An Updated Review. Cardiac Failure Review. 2023;9:e11. DOI: https://doi.org/10.15420/cfr.2023.05.
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology With the special contribution of the Heart Failure Association of the ESC. European Heart Journal. 2023;44(37):3627-3639. DOI: https://doi.org/10.1093/eurheartj/ehad195.
3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology With the special contribution of the Heart Failure Association of the ESC. European Heart Journal. 2021;42(36):3599-3726. DOI: https://doi.org/10.1093/eurheartj/ehab368.
4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. DOI: https://doi.org/10.1161/CIR.000000000000 1063.
5. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. «Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis». Diabetes, Obesity and Metabolism. 2018;20:479-487.
6. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019;381:1995-2008. DOI: 10.1056/NEJMoa1911303.
7. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine. 2020;383:1413-1424. DOI: 10.1056/NEJMoa2022190.
8. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2022;387:1089-1098.
9. Butler J, Filippatos G, Siddiqi TJ, Ferreira JP, Brueckmann M, Bocchi E, et al. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation. 2022;146:1046-1055. DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.059755.
10. Lopaschuk G, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-ofthe-Art Review. Journal of American College of Cardiology Basic to Translational Science. 2020 June;5(6):632-644. DOI: https://doi. org/10.1016/j.jacbts.2020.02.004.
11. Caminiti G, Sposato B, Volterrani M.Chronic heart failure: the role of di vericiguat. European Heart Journal Supplements. 2023;25:C316-C318. DOI: https://doi.org/10.1093/eurheartjsupp/suad056.
12. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. The SOCRATESREDUCED Randomized Trial. Journal of the American Medical Association. 2015;314(21):2251-2262. DOI: 10.1001/jama.2015.15734.
13. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2020;382:1883-1893. DOI: 10.1056/NEJMoa1915928.
14. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2021;23(6):872-881. DOI: https://doi.org/10.1002/ejhf.2206.
15. Tran BA, Serag-Bolos ES, Fernandez J, Miranda AC. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. Journal of Pharmacy Practice. 2023;36(4):905-914. DOI: https://doi.org/10.1177/08971900221087096.
16. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal. 2017;38:1119-1127.
17. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor CM, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. Journal of the American Medical Association. 2020;324:1512-1521.
18. Official site of the Merck Company. Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event. NJ: Merck & Co; 2021. Available from: https://www.merck.com/news/merck-announces-initiation-of-phase-3-study-evaluating-verquvo-vericiguat-in-patientswith-chronic-heart-failure-and-reduced-ejection-fraction-who-have-not-had-a-recent-worsening-heart-failure/.
19. Liu Y, White HD, Belknap B, Winkelmann DA, Forgacs E. Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin. Biochemistry. 2015;54:1963-1975. DOI: http://dx.doi.org/10.1021/ bi5015166.
20. Bavry AA, Bhatt DL, Eagle KA. Global Approach to lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart FailureGALACTIC-HF. Washington: American College of Cardiology; 2023.
21. Official site of the US Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee Meeting Announcement. Maryland: FDA; 2022. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/december-13-2022- cardiovascular-and-renal-drugs-advisory-committee-meeting-announcement-12132022.
22. Official site of the MedChemExpress. Vemtoberant. NJ: MedChemExpress. Available from: https://www.medchemexpress.com/ vemtoberant.html.
23. Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, et al. Antisense Inhibition of Angiotensinogen with IONIS-AGT-LRx. Journal of American College of Cardiology Basic to Translational Science. 2021 Jun;6(6):485-496. DOI: 10.1016/j.jacbts.2021.04.004.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 1, 172, 20-24 pages, index UDC 616.12-008.46-036.12-078-085.22

DOI:

10.29254/2077-4214-2024-1-172-20-24